FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileDefinium Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
DFTX
Definium Therapeutics, Inc. Stock AnalysisComprehensive stock analysis for Definium Therapeutics, Inc. (DFTX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisDFTX
DFTX
Definium Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
DFTX
  1. Home
  2. Stocks
  3. Definium Therapeutics, Inc.

Definium Therapeutics, Inc.

🇺🇸DFTX•NASDAQ

Definium Therapeutics, Inc.

🇺🇸DFTX•NASDAQ
Market cap
$3.99B

Your view on DFTX

Mkt Cap
$3.99B
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Definium Therapeutics, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Robert Barrow
Headquarters
One World Trade Center, New York, NY, US
Industry
Biotechnology
Sector
Healthcare
CEO
Robert Barrow
Headquarters
One World Trade Center, New York, NY, US
Description

Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders.

Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD).

Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Definium Therapeutics, Inc.. Starting points for Definium Therapeutics, Inc.: EPS -$2.48, beta 2.21 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Definium Therapeutics, Inc.. Trailing twelve-month EPS for Definium Therapeutics, Inc. stands at -$2.48. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Definium Therapeutics, Inc.. Definium Therapeutics, Inc. has reported as a listed company since 2016. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold DFTX12 companies
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PLRZPolyrizon Ltd.HealthcareNASDAQ$12.4M
PLURPluri Inc.HealthcareNASDAQ$9.9M
PLXProtalix BioTherapeutics, Inc.HealthcareAMEX$254.6M
PLYXPolaryx Therapeutics, Inc. Common StockHealthcareNASDAQ$80.3M
PMCBPharmaCyte Biotech, Inc.HealthcareNASDAQ$3.0M
PMNProMIS Neurosciences, Inc.HealthcareNASDAQ$28.2M
PMVPPMV Pharmaceuticals, Inc.HealthcareNASDAQ$65.1M
POLBFPoolbeg Pharma PLCHealthcareOTC$46.6M
PPBTPurple Biotech Ltd.HealthcareNASDAQ$236,124
PPCBPropanc Biopharma Inc. Common StockHealthcareNASDAQ$1.8M
PPTDFPeptiDream Inc.HealthcareOTC$1.1B
PRAXPraxis Precision Medicines, Inc.HealthcareNASDAQ$8.5B
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Definium Therapeutics, Inc., and how their positions are changing. At a $3.99B market value, institutional positions materially move Definium Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Definium Therapeutics, Inc. executives and directors. Shares of Definium Therapeutics, Inc. have traded between $12.88 and $49.20 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Definium Therapeutics, Inc.. Coverage tracks Definium Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Definium Therapeutics, Inc.

DFTX AnalysisFair
Past
5
Growth
2
Health
5
Profit
1
Value
1

News

Latest Market News